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Abstract
Background: Erythropoiesis stimulating agent (ESA)-resistant anemia is common in chronic kidney disease (CKD).
Objectives: To evaluate the determinants of severity of ESA resistance in patients with CKD and primary
ESA-resistance.
Design: Secondary analysis of a randomized controlled trial (the Handling Erythropoietin Resistance with
Oxpentifylline, HERO)
Setting and patients: 53 adult patients with CKD stage 4 or 5 and primary ESA-resistant anemia (hemoglobin ≤120 g/L,
ESA resistance index [ERI] ≥1.0 IU/kg/week/gHb for erythropoietin or ≥0.005 μg/kg/week/gHb for darbepoeitin, no cause
for ESA-resistance identified).
Measurements: Iron studies, parathyroid hormone, albumin, liver enzymes, phosphate or markers of oxidative stress and
inflammation.
Methods: Participants were divided into tertiles of ERI. Multinomial logistic regression was used to analyse the
determinants of ERI tertiles.
Results: All patients, except one, were receiving dialysis for end-stage kidney disease. The mean ± SD ERI values in the
low (n = 18), medium (n = 18) and high (n = 17) ERI tertiles were 1.4 ± 0.3, 2.3 ± 0.2 and 3.5 ± 0.8 IU/kg/week/gHb,
respectively (P < 0.001). There were no significant differences observed in age, gender, ethnicity, cause of kidney disease,
diabetes, iron studies, parathyroid hormone, albumin, liver enzymes, phosphate or markers of oxidative stress and
inflammation between the ERI tertiles. The median [inter-quartile range] serum alkaline phosphatase concentrations in
the low, medium and high ERI tertiles were 89 [64,121], 99 [76,134 and 148 [87,175] U/L, respectively (P = 0.054). There
was a weak but statistically significant association between ERI and serum alkaline phosphatase (R2 = 0.06, P = 0.03).
Using multinomial logistic regression, the risk of being in the high ERI tertile relative to the low ERI tertile increased with
increasing serum alkaline phosphatase levels (P = 0.02). No other variables were significantly associated with ERI.
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Limitations: Small sample size; bone-specific alkaline phosphatase, other markers of bone turnover and bone biopsies
not evaluated.
Conclusions: Serum alkaline phosphatase was associated with severity of ESA resistance in ESA-resistant patients with
CKD. Large prospective studies are required to confirm this association. (Trial registration: Australian New Zealand Clinical
Trials Registry 12608000199314)
Keywords: Erythropoiesis stimulating agents, Anemia, Chronic kidney disease, Alkaline phosphatase, Biological marker,
Risk factors, Randomized controlled trial
Résumé
Contexte: L’anémie résistante à l’agent stimulant l’érythropoïèse (ASE) est courante chez les patients atteints
d’insuffisance rénale chronique (IRC).
Objectifs: Évaluer les déterminants de la gravité de la résistance à l’ASE chez les patients atteints d’IRC et de la
résistance primaire à l’ASE.
Type d’étude: Analyse secondaire d’un essai clinique randomisé (le Handling Erythropoietin Resistance with
Oxpentifylline, HERO)
Contexte et participants: 53 patients adultes atteints d’IRC de stade 4 ou 5, de même que d’anémie résistante à
l’ASE (hémoglobine ≤120 g/L, indice de résistance à l’ASE [IRA] ≥1,0 IU/kg/semaine/gHb pour l’érythropoïétine ou
≥0,005 μg/kg/semaine/gHb pour la darbépoétine, aucune cause justifiant la résistance à l’ASE).
Mesures: Mesure des taux de fer, de la parathormone, de l’albumine, de l’enzyme hépatique, du phosphate ou des
marqueurs de stress oxydatif et d’inflammation.
Méthodes: Les participants étaient divisés en tertiels d’IRA. La méthode de régression logistique multinominale a
été utilisée pour analyser les déterminants des tertiels d’IRA.
Résultats: Tous les patients, sauf un, recevaient une dialyse pour l’IRT. La moyenne ± ÉT des valeurs d’IRA des
tertiels inférieur (n = 18), intermédiaire (n = 18) et supérieur (n = 17) étaient respectivement de 1,4 ± 0,3, de 2,3 ± 0,2
et de 3,5 ± 0,8 IU/kg/semaine/gHb (P < 0,001). On n’a observé aucune différence importante en fonction de l’âge,
du sexe, de l’ethnicité, de la cause de l’insuffisance rénale, du diabète, des taux de fer, de la parathormone, de
l’albumine, de l’enzyme hépatique, du phosphate ou des marqueurs de stress oxydatif et d’inflammation entre les
tertiels d’IRA. La médiane [écart interquartile] des concentrations de phosphatase alcaline sérique des tertiels d’IRA
inférieur, intermédiaire et supérieur étaient respectivement de 89 [64,121], de 99 [76,134] et de 148 [87,175] U/L
(P = 0,054). Bien que statistiquement significative, la relation était plutôt faible entre l’IRA et la phosphatase alcaline
sérique (R2 = 0,06; P = 0,03). Selon la méthode de régression logistique multinominale, les chances de se retrouver
dans le tertiel d’IRA supérieur, par opposition au tertiel d’IRA inférieur, augmentait avec des taux élevés de
phosphatase alcaline sérique (P = 0,02). On n’a observé aucune association forte entre une autre variable et l’IRA.
Conclusion: La phosphatase alcaline sérique a été associée à une forte résistance à l’ASE chez les patients résistants
à l’ASE atteints d’IRC. Des études prospectives à grande échelle sont nécessaires afin de confirmer cette association.
(Enregistrement de l’essai clinique: Australian New Zealand Clinical Trials Registry 12608000199314)
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Short section
What was known before
Increased serum alkaline phosphatase is associated with
decreased responsiveness to erythropoiesis stimulating
agents in patients with end-stage kidney disease.
What this study adds
Serum alkaline phosphatase is associated with severity of
resistance to erythropoiesis stimulating agents in patients
with chronic kidney disease with no identifiable causes for
resistance to erythropoiesis stimulating agents.
Background
Since the introduction of erythropoiesis stimulating agents
(ESA), there have been substantial reductions in the blood
transfusion requirements of patients suffering from chronic
kidney disease (CKD) [1]. Unfortunately, 7–14 % of all pa-
tients with end-stage kidney disease (ESKD) show a sub-
optimal hematologic response to ESA (Hb concentration
<100 g/L) [2–4]. There are several known causes of sub-
optimal response to ESA. These include: female gender;
[5–8] old age; [7] diabetes mellitus; [9] cardiovascular
disease; [5] lower body mass index; [10] malnutrition; [5, 7,
8, 10, 11] inflammation; [5, 9–14] deficiencies of iron, [7, 8,
10, 14, 15] vitamin B12, [16] folate [17] or vitamin D; [18]
hyperphosphatemia; [19] hyperparathyroidism; [13, 15]
elevated levels of serum alkaline phosphatase; [15] inad-
equate dialysis; [8] infection; [7, 20, 21] malignancy; [7] use
of ACE inhibitors or angiotensin receptor blockers; [13, 22]
presence of a failed kidney transplant; [23] and anti-
erythropoietin antibodies [24]. However, after excluding
these conditions, a significant proportion of patients exhibit
primary ESA-resistant anemia. The incidence and factors
responsible for primary resistance to ESA are unknown.
ESA treatment targeting hemoglobin levels above
130 g/L in people with CKD is associated with deleterious
[25] or neutral [26] impacts on survival and increased risks
of stroke, vascular access thrombosis and hypertension
without any reduction in cardiovascular events [25, 26].
However, recently published studies have demonstrated
that poor response to ESA treatment, rather than achieved
high hemoglobin, is associated with the observed adverse
outcomes in CKD [2, 14, 27–30]. Unfortunately, there are
no established therapies for primary ESA-resistant anemia
[31]. The Handling Erythropoietin Resistance with Oxpen-
tifylline (HERO) trial evaluated the effect of pentoxifylline
on erythropoiesis resistance index (ERI) in patients with
advanced CKD and primary ESA-hyporesponsive anemia
[32]. We conducted a post-hoc analysis of the HERO Study
to evaluate the determinants of severity of ESA resistance.
Methods
Details of the HERO Study protocol and population are
described elsewhere [32, 33]. In brief, the HERO Study
(registration number Australian New Zealand Clinical
Trials Registry 12608000199314) was a multi-centre,
double-blind, randomized placebo-controlled trial to
study the effect of pentoxifylline on ERI. The study was
approved by ethics committees at all participating centres.
All patients provided written informed consent prior to
trial participation and the trial was conducted in accord-
ance with the principles of the International Conference
on Harmonisation Good Clinical Practice Guideline.
Between June 2009 and December 2011, the study en-
rolled 53 adult patients with stages 4 or 5 CKD (receiving
dialysis treatment or estimated GFR <30 ml/min/1.73 m2)
and ESA- resistant anemia on a stable dose of either
erythropoietin or darbepoetin for at least 8 weeks.
ESA-resistant anemia was defined as hemoglobin con-
centration ≤120 g/L and ERI ≥1.0 IU/kg/week per g/L
for erythropoietin and ≥0.005 μg/kg/week per g/L for
darbepoetin. ERI was calculated as weight-adjusted
weekly dose of ESA divided by hemoglobin concentration,
(expressed as IU/kg/week per g/L). ERI for darbepoetin-
treated patients was converted to an erythropoietin-
equivalent value using a dose conversion factor of 200:1.
Patients with an identifiable cause for their ESA hypore-
sponsiveness (such as iron deficiency, bleeding, inadequate
dialysis, parathyroid hormone >100 pmol/L, malignancy
or hematologic disorder, major surgery, infection, acute
myocardial infarction or malignancy within the last
3 months) were excluded. Participants were randomized
in a 1:1 ratio to receive pentoxifylline (Trental®, Sanofi-
Aventis, Sydney, Australia) 400 mg daily orally or an iden-
tical matching placebo. The randomization was performed
by an adaptive allocation algorithm designed to minimize
imbalance in treatment groups across three variables:
study site; CKD stage (4 or 5) and ESA class (erythropoietin
or darbepoetin) using a password-protected web-based sys-
tem. The follow up period was 4 months, unless a partici-
pant experienced a hemoglobin concentration <65 g/L or
required a blood transfusion. The primary efficacy outcome
was ERI. Secondary outcome variables were hemoglobin
concentration, ESA dose, rate of blood transfusions, ad-
verse events, quality of life and cost-effectiveness analysis.
Of the 53 participants, plasma samples for four oxidative
stress biomarkers (total F2-isoprostanes, protein carbonyls,
glutathione peroxidase [GPX] and superoxide dismutase
[SOD] activities) were available in 41 participants.
Statistical analysis
This post-hoc analysis included only the baseline data
from the main HERO Study and oxidative stress sub-
study. Results were expressed as frequencies (percent-
ages) for categorical variables, mean ± standard deviation
for continuous normally distributed variables and me-
dian [interquartile range] for continuous non-normally
distributed variables. Participants were divided into
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Table 1 Baseline characteristics according to tertiles of ERI
Variable ERI tertile P
Low Medium High
n 18 18 17
ERI (IU/kg/wk/gHb) 1.4 ± 0.3 2.3 ± 0.2 3.5 ± 0.8 <0.001
ESA dose (IU/kg/wk)a 153 ± 37 233 ± 25 362 ± 79 <0.001
Type of ESA 0.8
Erythropoietin 11 (61 %) 12 (67 %) 12 (71 %)
Darbepoetin 7 (39 %) 6 (33 %) 5 (29 %)
Hemoglobin (g/L) 111 ± 8 102 ± 13 105 ± 10 0.05
Men 10 (56 %) 8 (44 %) 6 (35 %) 0.5
Age (years) 67.7 ± 13 58.4 ± 17.6 60.5 ± 15.5 0.2
Ethnicity 0.4
Caucasian 14 (78 %) 14 (78 %) 15 (88 %)
Aboriginal or Torres Strait Islander 0 1 (6 %) 0
Maori/Pacific Islander 0 1 (6 %) 0
Asian 3 (17 %) 2 (11 %) 0
Other 1 (6 %) 0 2 (12 %)
Cause of kidney diseaseb 0.9
Diabetes 8 (44 %) 8 (47 %) 5 (29 %)
Glomerulonephritis 2 (11 %) 1 (6 %) 4 (24 %)
Analgesic nephropathy 0 1 (6 %) 0
Polycystic kidney disease 1 (6 %) 1 (6 %) 1 (6 %)
Reflux nephropathy 1 (6 %) 1 (6 %) 1 (6 %)
Renovascular disease 0 1 (6 %) 1 (6 %)
Others 6 (33) 4 (24 %) 5 (29 %)
Type of dialysisb 0.4
Hemodialysis 17 (94 %) 16 (94 %) 17 (100 %)
Peritoneal dialysis 1 (6 %) 0 0
Pre-dialysis 0 1 (6 %) 0
Diabetes mellitusc 10 (67 %) 9 (82 %) 6 (46 %) 0.2
Ischemic heart diseasec 7 (47 %) 4 (36 %) 7 (54 %) 0.7
Congestive heart failurec 2 (13 %) 1 (9 %) 5 (38 %) 0.1
Cerebrovascular diseasec 1 (7 %) 0 3 (23 %) 0.2
Peripheral vascular diseasec 2 (13 %) 4 (36 %) 4 (31 %) 0.4
Smoking statusb 0.3
Never 9 (50 %) 5 (29 %) 9 (53 %)
Former 8 (44 %) 11 (65 %) 5 (29 %)
Current 1 (6 %) 1 (6 %) 3 (18 %)
Body mass index (kg/m2) 28.6 ± 4.8 30.4 ± 7.4 29.2 ± 7.6 0.7
Body mass index category 0.3
Underweight (<18.5 kg/m2) 0 0 0
Healthy weight (18.5 – 24.9 kg/m2) 5 (28 %) 4 (22 %) 6 (35 %)
Overweight (25 – 29.9 kg/m2) 9 (50 %) 6 (33 %) 3 (18 %)
Obese (>30 kg/m2) 4 (22 %) 8 (44 %) 8 (47 %)
Hematocrit (%) 34 ± 3 32 ± 5 32 ± 3 0.7
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Fig. 1 Scatterplot showing the association between serum alkaline phosphatase and ESA resistance index
Table 1 Baseline characteristics according to tertiles of ERI (Continued)
Mean cellular volume (fL) 94.4 ± 7.8 95.3 ± 6.6 94.3 ± 5.9 0.9
Reticulocyte count (109/L) 57 ± 21 74 ± 38 64 ± 31 0.3
Total white cell count (x 109 per L) 6.8 ± 2 6.4 ± 2.1 6.6 ± 1.5 0.9
Platelet count (x 109 per L)d 207 [164, 286] 188 [167, 207] 197 [164, 274] 0.8
Ferritin (μg/L)d 413 [241, 958] 527 [298, 647] 487 [315, 594] 0.9
Transferrin saturation (%)d 26 [20, 30] 22 [17, 30] 23 [22, 29] 0.6
Serum bicarbonate (mmol/L) 23.3 ± 4 22.6 ± 3 23.6 ± 3 0.6
Albumin (g/L) 36 ± 4 35 ± 4 35 ± 5 0.7
Serum alkaline phosphatase (U/L)d 89 [64, 121] 99 [76, 134] 148 [87, 175] 0.054
Gamma-glutamyltransferase (U/L)d 23 [16, 40] 25 [17, 60] 32 [21, 57] 0.4
Alanine transaminase (U/L)d 16 [11, 19] 15 [9, 22] 10 [8, 19] 0.2
Aspartate transaminase (U/L)d 18 [13, 22] 17 [12, 23] 14 [10, 17] 0.3
Lactate dehydrogenase (U/L) 224 ± 57 224 ± 85 265 ± 63 0.2
Albumin-corrected calcium (mmol/L) 2.3 ± 0.2 2.3 ± 0.1 2.2 ± 0.2 0.2
Phosphate (mmol/L)e 1.7 ± 0.5 1.7 ± 0.5 1.7 ± 0.5 0.9
Parathyroid hormone (pmol/L)d,f 17 [9, 35] 33 [17, 42] 32 [16, 65] 0.2
C-reactive protein (mg/L) 3 [2, 21] 12 [4, 28] 15 [7, 31] 0.06
Oxidative stress substudy
n 14 13 14
Total F2-isoprostanes (pg/mL)d 133 [87, 213] 143 [128, 200] 112 [67, 173] 0.3
Glutathione peroxidise activity (U/L) 177 (13) 181 (10) 174 (14) 0.4
Superoxide dismutase activity (U/mL)d,f 1.97 [1.41, 2.6] 2.01 [1.32, 2.44] 2.22 [1.71, 2.71] 0.7
Protein carbonyls (nmol/mg)d 0.56 [0.46, 0.6] 0.55 [0.46, 0.74] 0.55 [0.51, 0.69] 0.9
aPatients on darbepoetin were converted to an erythropoietin-equivalent dose using a conversion factor of 200:1
b1 missing data from medium ERI tertile
cMissing data- 3, 7 and 4 values missing from low, medium and high ERI tertiles, respectively
dMedian [IQR]
eto convert phosphate level from mmol/L to mg/dL multiply by 3.1
fto convert parathyroid level from pmol/L to pg/mL multiply by 9.4
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tertiles of ERI (low, medium and high ERI). Differences
between groups of patients were analysed by χ2 test for
categorical data; one-way analysis of variance for con-
tinuous variables if data were normally distributed and
Kruskal–Wallis test for non-normally distributed data.
Simple linear regression was used to analyze the associ-
ation between ERI and other variables. Non-normally
distributed variables were appropriately transformed to
improve normality of distribution. Associations be-
tween ERI and the following variables were analysed in
linear regression models: gender, ethnicity, diabetes
mellitus, cause of kidney disease, smoking status, ische-
mic heart disease, congestive heart failure, and body
mass index category, age, reticulocyte count, total white
cell count, ferritin, transferrin saturation, albumin, alkaline
phosphatase, gamma-glutamyltransferase, alanine trans-
aminase, aspartate transaminase, lactate dehydrogenase,
albumin-corrected calcium, phosphate, parathyroid hor-
mone, C-reactive protein, total F2-isoprostanes, protein
carbonyls, GPX and SOD activities. Predictors of high ERI
tertile versus low and medium ERI tertiles were deter-
mined by univariate multinomial logistic regression
models. The same above mentioned variables were used in
these models. Analysis was conducted using Stata/SE
(version 11.2, Stata Corp., College Station, TX, USA).
Results
Patient characteristics
Baseline characteristics of the study population accord-
ing to ERI tertiles are described in Table 1. The mean
ERI values in the low, medium and high ERI tertiles
were 1.4 ± 0.3, 2.3 ± 0.2 and 3.5 ± 0.8 IU/kg/week/gHb,
respectively. Increasing ERI was associated with both
higher ESA dose and lower hemoglobin level (Table 1).
Serum alkaline phosphatase concentrations also in-
creased with increasing ERI. Median [IQR] serum alka-
line phosphatase levels in the low, medium and high ERI
tertiles were 89 [64, 121], 99 [76, 134] and 148 [87, 175]
U/L, respectively (P = 0.054, Table 1). There were no sta-
tistically significant differences observed between the
ERI tertiles with respect to age, gender, ethnic origin,
cause of kidney disease, smoking status, dialysis modal-
ity, comorbidities, body mass index, other laboratory
values or oxidative stress markers (Table 1).
Determinants of ESA resistance index
Using simple linear regression, there was a weak but sta-
tistically significant association between ERI and alkaline
phosphatase (R2 = 0.06, P = 0.03) (Fig. 1). On multi-
nomial logistic regression, the risk of being in the high
ERI tertile relative to the low ERI tertile increased with
increasing alkaline phosphatase levels (P = 0.02). No
other variables were significantly associated with ERI on
univariate analysis (Tables 2 and 3).
Discussion
This secondary analysis of the HERO Study showed that
serum alkaline phosphatase was associated with severity
of ESA resistance in a selected group of patients with
advanced CKD who did not have any identifiable cause
of ESA-resistant anemia. No other factors were found to
be associated with severity of ESA resistance.
In a study involving 38,328 ESKD patients receiving
hemodialysis, Kalantar-Zadeh and colleagues reported a
positive association between serum alkaline phosphatase
level and ESA hyporesponsiveness [15]. Importantly, this
association persisted even after adjusting for other known
causes of anemia, such as older age, gender, diabetes
Table 2 Associations between participant characteristics and
ERI by simple linear regression
Variable R2 P value
Women (Reference men) −0.02 0.8
Non-Caucasians (Reference Caucasians) −0.02 0.7
Diabetes mellitus (Reference non-diabetics) 0.01 0.2
Cause of kidney disease −0.03 0.6
Smoking status −0.02 0.6
Body mass index 0.02 0.2
Ischemic heart disease −0.01 0.4
Congestive heart failure 0.02 0.2
Age 0.01 0.2
Reticulocyte count −0.01 0.6
Total white cell count −0.02 0.8
Ferritina −0.01 0.5
Transferrin saturationb −0.01 0.6
Albumin 0.001 0.3
Alkaline phosphatasec 0.06 0.03
Gamma-glutamyltransferaseb 0.01 0.2
Alanine transaminasec 0.02 0.1
Aspartate transaminasec 0.04 0.09
Lactate dehydrogenaseb 0.07 0.05
Albumin-corrected calcium 0.05 0.06
Phosphate −0.02 0.9
Parathyroid hormonea 0.04 0.09
C-reactive protein 0.03 0.09
Total F2-isoprostanesb −0.01 0.5
Glutathione peroxidise activityd −0.004 0.9
Superoxide dismutase activitye −0.01 0.5
Protein carbonylse −0.03 0.9
The following non-normally distributed variables were transformed to normality
of distribution:
asquare root
blog-transformed
creciprocal of square root
dpower of 3
ereciprocal
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Table 3 Associations between participant characteristics and ERI by univariate multinomial logistic regression
Variable Coefficient 95 % confidence intervals P value
Women (Reference men) −0.83 −2.19 to 0.53 0.2
Non-Caucasians (Reference Caucasians) 0.76 −1.08 to 2.61 0.4
Diabetes mellitus (Reference non-diabetics) 0.85 −0.68 to 2.38 0.3
Cause of kidney disease
Diabetes Reference
Glomerulonephritis −1.16 −3.19 to 0.87 0.3
Analgesic nephropathy NR NR NR
Polycystic kidney disease −0.47 −3.46 to 2.52 0.8
Reflux nephropathy −0.47 −3.46 to 2.52 0.8
Renovascular disease NR NR NR
Others −0.29 −1.92 to 1.34 0.7
Smoking status
Never Reference
Former 0.47 −0.98 to 1.92 0.5
Current −1.10 −3.54 to 1.35 0.4
Body mass index category
Healthy weight Reference
Overweight 1.28 −0.48 to 3.05 0.2
Obese −0.51 −2.20 to 1.18 0.6
Ischemic heart disease −0.28 −1.78 to 1.20 0.7
Congestive heart failure −1.40 −3.26 to 0.46 0.1
Age 0.03 −0.01 to 0.08 0.2
Reticulocyte count −0.01 −0.03 to 0.02 0.5
Total white cell count 0.03 −0.33 to 0.40 0.9
Ferritina 0.01 −0.09 to 0.11 0.8
Transferrin saturationb 0.05 −2.29 to 2.39 0.9
Albumin 0.06 −0.09 to 0.21 0.4
Alkaline phosphatasec 44.01 7.63 to 80.40 0.02
Gamma-glutamyltransferaseb −0.65 −1.60 to 0.30 0.2
Alanine transaminasec −7.42 −16.80 to 1.96 0.1
Aspartate transaminasec −8.50 −20.62 to 3.62 0.2
Lactate dehydrogenaseb −2.18 −5.06 to 0.69 0.1
Albumin-corrected calcium 3.46 −0.60 to 7.51 0.09
Phosphate −0.01 −1.31 to 1.29 0.9
Parathyroid hormonea −0.25 −0.55 to 0.05 0.1
C-reactive protein −0.03 −0.08 to 0.01 0.2
Total F2-isoprostanesb 0.36 −0.69 to 1.42 0.5
Glutathione peroxidise activityd NR NR NR
Superoxide dismutase activitye 1.49 −1.91 to 4.90 0.4
Protein carbonylse 0.24 −1.26 to 1.74 0.8
NR Estimates could not be obtained due to small number of patients
The following non-normally distributed variables were transformed to normality of distribution:
asquare root
blog-transformed
creciprocal of square root
dpower of 3
e reciprocal
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mellitus, body mass index, iron studies, markers of bone
disease, parathyroid level and markers of malnutrition.
Other investigators have reported improvement in
hemoglobin concentration and reductions in the serum al-
kaline phosphatase level and ESA dose after parathyroid-
ectomy [34, 35]. Previous studies have also demonstrated
that alkaline phosphatase is associated with mortality in
ESKD patients receiving dialysis [36–39] and pre-dialysis
patients with CKD [40–43]. A major difference between
the present study and previous investigations is that the
HERO study excluded patients with any identifiable cause
of ESA-resistant anemia, such as deficiencies of iron or
vitamin B12 or folate, bleeding, inadequate dialysis, severe
hyperparathyroidism (PTH >100 pmol/L), malignancy or
hematologic disorder, major surgery, infection, acute myo-
cardial infarction or malignancy within the last 3 months.
Indeed, this is the first study describing the determi-
nants of severity of ESA resistance in patients with pri-
mary ESA-resistance, as previous studies included
patients with no ESA resistance as well as those with
known secondary causes of ESA resistance.
Approximately 31–37 % of ESKD patients receiving
dialysis have raised levels of serum alkaline phosphatase
[36, 44]. Serum alkaline phosphatase in the dialysis
population is strongly associated with serum concentra-
tions of parathyroid hormone and aspartate transamin-
ase [36]. Although bone and liver alkaline phosphatase
are found in equal proportions in healthy adults, 28 % of
ESKD patients on haemodialysis with increased bone
alkaline phosphatase have normal alkaline phosphatase
levels [44]. In a study involving 800 ESKD patients re-
ceiving haemodialysis, Drechsler and colleagues showed
a strong association between bone alkaline phosphatase
and all-cause and cardiovascular mortality [37].
The most likely reason for the observed association be-
tween alkaline phosphatase and severity of ESA resistance
in the present study is increased bone turnover and mar-
row fibrosis, since the median serum PTH levels in the
middle and high ERI tertiles were 33 and 32 pmol/L, re-
spectively compared with 17 pmol/L in the low ERI tertile
[45]. In the current study, there was no statistically signifi-
cant association observed between parathyroid hormone
and primary ESA-resistance. It is important to note that
the HERO Study excluded patients with a serum parathy-
roid hormone level greater than 100 pmol/L, such that in-
cluded patients only had mild-to-moderate secondary
hyperparathyroidism. Nevertheless, even at these relatively
modest elevations of serum PTH, alkaline phosphatase
was still significantly associated with ESA resistance.
A strength of the study was that it involved patients
from multiple centers across two countries, enhancing the
internal and external validity of the findings. On the other
hand, the study was limited by a relatively small sample
size, such that it is possible that some associations with
severity of ESA resistance were not able to be ascertained
due to a type 2 statistical error. Moreover, as multiple vari-
ables were evaluated in this study, the observed associ-
ation between alkaline phosphatase and severity of ESA
resistance could have been due to a type 1 statistical error.
Bone-specific alkaline phosphatase, other markers of bone
turnover and bone biopsies were not evaluated, thereby
limiting more detailed exploration of the potential mecha-
nisms underpinning the association between serum alka-
line phosphatase and severity of ESA resistance. Since the
HERO study included a highly selected group of patients
with no identifiable cause of ESA-resistant anemia, the
findings of this study may not be generalizable to patients
with a known cause of ESA hyporesponsiveness. This find-
ing is hypothesis generating and needs to be confirmed by
other studies.
Conclusions
Alkaline phosphatase was associated with severity of ESA
resistance in patients with advanced CKD and no apparent
secondary cause of ESA-resistance. Larger prospective
studies are required to confirm this association.
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